HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cognis touts naturals portfolio

This article was originally published in The Rose Sheet

Executive Summary

German fragrance and flavor supplier announces availability of 63 ingredients certified to Natural Products Association standards (see story, p. 3). "For Cognis Care Chemicals, natural renewable raw materials provide the backbone of our product portfolio - from primary surfactants to active ingredients," states Josef Koester, the division's North American director of marketing. Firm highlights Eumulgin SG, "a high-performance, powerful emulsifier," and Plantasil Micro, "a hair-care additive for green shampoos," as well as Euperlan Green and its APG surfactants, which continue to rank among its "natural stars" (1"The Rose Sheet" Nov. 24, 2008). "We are really excited to work closely with the NPA because we're committed to giving our customers the information they need to choose products that are right for them," says Cognis' Denise Petersen, marketing manager for Cognis Care Chemicals North America

You may also be interested in...



Cognis Directs Green-Seeking Customers To Its “Natural Stars”

To companies with an eye toward sustainability, Cognis recommends its "natural stars," the most eco-friendly, functional and affordable of its natural offering - the cream of its green crop

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.

Global Pharma Guidance Tracker – March 2024

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016607

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel